NAD Press Releases

NAD Examines Ratings Claims for ‘MyPurMist Handheld Steam Inhaler,’ Recommends Vapore Discontinue ‘More 5-Star Reviews’ Claim

NAD has recommended that Vapore, LLC, maker of the “MyPurMist Handheld Steam Inhaler,” discontinue the express claim that its product has more “5-star reviews than any other steam inhaler,” as well as consumer testimonials made in broadcast and Internet advertising.

Read More

NAD Refers Advertising Claims made by Shredlage, CLAAS to FTC for Further Review After Farm Equipment Companies Decline to Participate in NAD Inquiry

NAD has referred advertising claims made Shredlage, LLC and CLAAS of America to the Federal Trade Commission (FTC) for further review, after the companies declined to participate in a review of advertising claims made for their corn kernel processing equipment.

Read More

NAD Finds P&G can Support Superior Line Claim For Oral-B Toothbrushes, Following Challenge by Philips Oral Healthcare

NAD has determined that the Procter & Gamble Company, maker of Oral-B electric toothbrushes, can support advertising claims challenged by competitor Philips Oral Healthcare, LLC.

Read More

NAD Recommends Philips Oral Healthcare Discontinue Two Commercials Challenged by P&G

NAD has recommended that Philips Oral Healthcare, LLC, discontinue two broadcast commercials for the company’s Sonicare brand electric toothbrushes, following a challenge from the Procter & Gamble Company, maker of Oral-B electric toothbrushes.

Read More

NAD Recommends Vestagen Discontinue Claims that Company’s ‘VESTEX’ Hospital Scrubs Protect Patients, Medical Personnel from Dangerous Contaminants; Finds Company can Support Certain Medical Device Claims

NAD has recommended that Vestagen Protective Technologies, Inc., discontinue certain advertising claims for the company’s Vestex fabric, including claims that garments made with Vestex fabric protect healthcare workers and their patients from pathogens, dangerous contaminants and healthcare-associated infections.

Read More

NAD Recommends Prevention Pharmaceuticals Discontinue Certain Claims for Company’s ‘Omax3 Ultra Pure’ Supplements; Finds Company Can Support Certain Qualified Claims

NAD has determined that Prevention Pharmaceuticals, Inc., can support certain qualified claims for the company’s Omax3 Ultra Pure Dietary Supplements. NAD has also recommended the company discontinue a wide range of claims, including market superiority purity, potency and compositional claims.

Read More